



Press release Stockholm 2022-09-27

Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients

Kancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company is also announcing that in order to strengthen the study further, the protocol has been amended to allow for recruitment of up to 10 additional patients. Consequently, completion of patient enrollment might be extended one month into January 2023.

The clinical study of KAND567 in myocardial infarction patients is being conducted by the NHS Foundation as sponsor at Freeman Hospital and James Cook Hospital in the UK. The primary objectives are to evaluate the safety profile and cardioprotective effect of KAND567 in patients with a major myocardial infarction in the anterior wall of the heart muscle (STEMI). The patient recruitment is progressing well, and 54 patients have been enrolled so far. During the study it was found however that complete sets of scheduled samples could not be retrieved from all patients. Therefore, the study protocol has been amended to allow for recruitment of ten additional patients to reach approximately 60 fully-evaluable study subjects. Based on the current enrollment rate, it is still likely that recruitment can be finalized before the end of 2022, but extension into January 2023 cannot be ruled out.

"We are very encouraged by the current enrollment rate and we support the sponsor making this protocol amendment as it is key to have a sufficient number of evaluable study subjects to be able to report on the primary endpoints with high quality.", says Thomas Olin, CEO of Kancera.

About Kancera AB (publ)

Kancera AB is developing a new class of drugs in the areas of inflammation and cancer, with a main focus on developing drug candidates based on the so called Fractalkine system. Fractalkine is a natural master regulator that controls immune cells and cancer cells with precision. Kancera is studying its most advanced drug candidate in an ongoing fully financed phase IIa study in inflammation in connection with myocardial infarction. Patient enrollment is expected to be completed before the end of 2022. Kancera is also conducting development of its drug candidate KAND145, primarily aimed for oncology indications. Fully financed phase I-studies are planned to start in H1 2023. The stock is traded on the Nasdaq First North Premier Growth Market.

For further information:

Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-8-5012 6080

Welcome to visit Kancera's web page: <https://www.kancera.com/en>